Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00374166 · ClinicalTrials.gov registry record · Phase 2
An Eight-week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Generalized Anxiety Disorder
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 325
- Enrollment target
NCT00374166 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 325 participants.
The verdict
NCT00374166, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 325 participants
- Enrollment target
Study Summary
The objective is to evaluate the efficacy and safety of two doses of SSR149415 (250 mg and 100 mg twice daily) compared to placebo and paroxetine 20 mg once daily in outpatients with generalized anxiety disorder
Interventions
- DRUG Placebo
- DRUG Paroxetine
- DRUG SSR149415
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 2006-08 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00374166
The ClinicalTrials.gov registry entry for NCT00374166 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 325 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00374166 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00374166 about?
NCT00374166 is a clinical study titled "An Eight-week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Generalized Anxiety Disorder". The objective is to evaluate the efficacy and safety of two doses of SSR149415 (250 mg and 100 mg twice daily) compared to placebo and paroxetine 20 mg once daily in outpatients with generalized anxiety disorder
What is the current status of trial NCT00374166?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 325 participants. The study started on 2006-08. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00374166?
The interventions under investigation include: Placebo (DRUG), Paroxetine (DRUG), SSR149415 (DRUG).
Who is sponsoring clinical trial NCT00374166?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.